Table 2.
Investigational status of new medical therapies for uterine leiomyomata
| Medication | Status | U.S. Clinical Trial Phase | Clinicaltrials.gov |
|---|---|---|---|
|
Selective progesterone receptor medications | |||
| Ulipristal Acetate | Approved in Europe, Asia, Canada for repeated intermittent use | VENUS I & II, complete NDA reported accepted 10/10/2017 |
NCT02147197 NCT02147158 |
| Viliprisan | Investigational | ASTEROID Phase III Study launched 8/7/2017 |
NCT03240523 NCT03194646 |
| Proellex | Investigational | Completed Phase II studies for vaginal and oral administration |
NCT00737282 NCT00683917 |
| GnRH antagonists | |||
| Elagolix | Investigational | Phase IIIb study completed, IIIb enrolling |
NCT02654054 NCT02691494 NCT03271489 |
| Relugolix | Investigational | Phase III LIBERTY 1 and 2 enrolling |
NCT03049735 NCT03103087 |
| OBE2109 | Investigational | Phase III PRIMROSE 1 and 2 enrolling |
NCT03070899 NCT03070951 |